MADISON, Wis., July 16 /PRNewswire-FirstCall/ -- Third Wave Technologies Inc. (Nasdaq: TWTI) today announced that it has signed a pharmacogenetics collaboration agreement with Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), one of the world’s largest reference laboratories and a pioneer in commercializing new diagnostic technologies, to develop a companion diagnostic to help physicians personalize treatment for heart failure patients.
